|Videos|July 7, 2016

The Ideal Patient Population for the Use of Nivolumab in Treatment of NSCLC

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the ideal patient population that can potentially benefit from the use of nivolumab in the treatment of non-small cell lung cancer.

Stay up to date on practice-changing data in community practice.

The Ideal Patient Population for the Use of Nivolumab in Treatment of NSCLC

Related Content

Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care

Life Years Saved: Why This Metric Better Reflects Progress in Blood Cancer

Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment

Purpose-Built Trials: Designing for Greater Patient Access

FDA Expands Sevabertinib Approval to Treatment-Naive HER2-Mutant NSCLC

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Washington State Medical Oncology Society

New Mexico Society of Clinical Oncology

Louisiana Oncology Society

Nevada Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

24th Annual School of Breast Oncology

Wisconsin Association of Hematology and Oncology

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap

INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC

Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment

Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC

Dabogratinib Shows Early Efficacy Signal in FGFR3-Altered NMIBC